| 2401BT-002P | A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) with Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma | Open |
| A071601-CIRB | Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas | Open |
| ACNS0332 | Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients | Open |
| ACNS0831 | Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with
Newly Diagnosed Ependymoma Ages 1 to 21 years | Open |
| ACNS1123 | Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized
Central Nervous System Germ Cell Tumors (CNS GCT) | Open |
| ANBL1221 | A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma | Open |
| ANBL1232 | Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma | Open |
| APEC1621SC | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) | Open |
| EF-25 | Pivotal, Open-Label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC) | Open |
| GO30140 | An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors. | Open |
| LOXO-TRK-15002 | A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors | Open |
| MCC-16962 | A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors | Open |
| MIBG-EXPANDED-ACCESS | An Open Label, Expanded Access Protocol Using 131i-Metaiodobenzylguanidine (131i-Mibg) Therapy In Patients With Refractory Neuroblastoma, Pheochromocytoma, Or Paraganglioma | Open |
| ML28897PRO/02 | My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents. | Open |
| NC-6300-001 | A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma | Open |
| NRG-BN003 | Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma | Open |
| OT-15-001 | A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
| Open |
| VEG116731 | A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors | Open |